FFM
Fairmount Funds Management Portfolio holdings
AUM
$772M
This Quarter Return
+28.55%
1 Year Return
+35.05%
3 Year Return
+1,168.51%
5 Year Return
+1,432.11%
10 Year Return
–
AUM
$236M
AUM Growth
+$236M
(+5.3%)
Cap. Flow
+$21.1M
Cap. Flow
% of AUM
8.94%
Top 10 Holdings %
Top 10 Hldgs %
83.82%
Holding
17
New
3
Increased
8
Reduced
6
Closed
–
Top Buys
| 1 |
Cogent Biosciences
COGT
|
$13.7M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$5.81M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$2.57M |
| 4 |
ZGNX
Zogenix, Inc.
ZGNX
|
$1.52M |
| 5 |
Insmed
INSM
|
$1.48M |
Top Sells
| 1 |
Neurogene
NGNE
|
$4.77M |
| 2 |
ALLK
Allakos
ALLK
|
$1.14M |
| 3 |
Amicus Therapeutics
FOLD
|
$706K |
| 4 |
Enanta Pharmaceuticals
ENTA
|
$353K |
| 5 |
Iovance Biotherapeutics
IOVA
|
$230K |
Sector Composition
| 1 | Healthcare | 90.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$28.8B
| $34M | 14.39% | 1,056,797 +46,000 | +5% | +$1.48M |
|
|
2
Acadia Pharmaceuticals
ACAD
$4.38B
| $26.7M | 11.32% | 647,833 +62,316 | +11% | +$2.57M |
|
|
TRIL
3
DELISTED
Trillium Therapeutics Inc.
TRIL
| $22.1M | 9.38% | 1,558,181 +75,000 | +5% | +$1.07M |
|
|
4
Amicus Therapeutics
FOLD
$2.34B
| $20.6M | 8.7% | 1,455,395 -50,000 | -3% | -$706K |
|
|
5
Iovance Biotherapeutics
IOVA
$807M
| $19.7M | 8.32% | 596,890 -7,000 | -1% | -$230K |
|
|
ZGNX
6
DELISTED
Zogenix, Inc.
ZGNX
| $19M | 8.03% | 1,056,875 +85,000 | +9% | +$1.52M |
|
7
Axsome Therapeutics
AXSM
$6.05B
| $15.7M | 6.64% | 220,098 +4,000 | +2% | +$285K |
|
|
8
Cogent Biosciences
COGT
$1.69B
| $13.7M | 5.81% | +6,235,903 | New | +$13.7M |
|
|
ALLK
9
DELISTED
Allakos
ALLK
| $13.4M | 5.68% | 164,662 -14,000 | -8% | -$1.14M |
|
10
argenx
ARGX
$43.6B
| $13.1M | 5.55% | 49,950 -500 | -1% | -$131K |
|
11
Karyopharm Therapeutics
KPTI
$61.7M
| $10.3M | 4.34% | 702,351 +50,000 | +8% | +$730K |
|
|
12
Enanta Pharmaceuticals
ENTA
$180M
| $7.43M | 3.15% | 162,236 -7,713 | -5% | -$353K |
|
|
AMRN
13
Amarin Corp
AMRN
$311M
| $6.35M | 2.69% | 1,508,237 +105,000 | +7% | +$442K |
|
|
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5.81M | 2.46% | +35,000 | New | +$5.81M |
|
|
15
Neurogene
NGNE
$264M
| $4.47M | 1.89% | 372,748 -397,325 | -52% | -$4.77M |
|
16
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $3.26M | 1.38% | 212,746 +12,621 | +6% | +$193K |
|
|
VRNA
17
Verona Pharma
VRNA
$9.16B
| $624K | 0.26% | +100,000 | New | +$624K |
|